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Background: Fatigue is rated as the most distressing side effect of radiotherapy treatment for curable breast cancer.
About four in ten women treated experience fatigue, which can last for years after treatment. The impact of this
debilitating tiredness is loss of independence and impaired physical and mental function. Our study will take a
behavioural intervention with demonstrated effect in treating fatigue in a mixed group of chemotherapy patients
and adapt it for women undergoing radiotherapy for early breast cancer. The purpose of this trial is to evaluate
the feasibility of delivering the intervention in the radiotherapy pathway for patients at a high risk of fatigue and
to explore participants’ experiences of the trial and intervention.
Methods: A pragmatic single-site non-blinded feasibility trial of a behavioural intervention. Main inclusion criteria
are prescription of the UK standard 40 Gy in 15 fractions over 3 weeks of radiotherapy (± tumour bed boost) for
early (stage 0–IIIa) breast cancer. The total projected sample size after attrition is 70. A previously developed fatigue risk
score tool will be used to predict individual’s likelihood of experiencing fatigue. Thirty women predicted to be at a
high risk of experiencing significant fatigue will be allocated in the ratio 2:1 to the behavioural intervention or education
trial arms, respectively. These feasibility trial participants will be assessed at baseline, after 10 and 15 fractions of
radiotherapy and 10 days, 3 weeks and 6 months after radiotherapy. A further 40 women predicted to be at a
lower risk of fatigue will join a risk score validation group.
Measures to assess feasibility include recruitment, retention and completion rates and variation in implementation of
the intervention. Process evaluation with intervention providers and users includes fidelity and adherence checks and
qualitative interviews to understand how changes in behaviour are initiated and sustained.
Discussion: This feasibility study collates data to both inform the progression to and design of a future definitive trial
and to refine the intervention.
Trial registration: ISRCTN 10303368. Registered August 2017 (retrospectively registered); Health and Care Research
Wales Clinical Research Portfolio (CRP) registration 31419.
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Breast cancer is the most common UK female malig-
nancy with 55,000 cases diagnosed annually [1]. Two
thirds of these women will undergo breast conserving
surgery followed by adjuvant radiotherapy to prevent
loco-regional recurrence. Selective prescription of sys-
temic anti-cancer therapies also contributes to a 5-year
survival of 87% for breast cancer [2]. Health policy ex-
pects that all survivors of cancer get the support they
need to lead active lives [3] and focusses on ‘interven-
tions to help people cope with the side-effects of treat-
ment’ [4].
Patients with early breast cancer rate fatigue as the most
distressing side effect of treatment and it is the predomin-
ant mediator of wellbeing in this population [5].
Radiotherapy-related fatigue (RRF) disrupts daily func-
tioning—the ability to return to work, to undertake family
responsibilities and to maintain social lives [6]—for
women who are often of working age (average age of diag-
nosis is 57 years) [7]. Four in ten women receiving radical
radiotherapy experience clinically significant fatigue [8, 9],
which can last for months, or years, after treatment [10].
This chronic fatigue is strongly associated with the sever-
ity at the end of adjuvant treatment [11].
Whilst results are mixed and pooled effect sizes small
to moderate, high-level review evidence reports psycho-
educational approaches have demonstrated effectiveness
on fatigue reduction (pooled mean effect size − 0.31;
range − 0.43 to 1.10, 95%CI − 0.38 to − 0.25) [12]. Effect-
ive fatigue interventions are brief, delivered individually
to specific disease and treatment groups and based on
need [13]. Participants in successful interventions were
broadly educated about fatigue, learnt to balance activ-
ities and rest, were provided with emotional support and
learnt self-management techniques [10]. Cognitive be-
havioural therapy (CBT)-orientated interventions have
shown promise (mean effect size 0.47) [12] in treating
fatigue in chronic fatigue syndrome, breast cancer survi-
vors and chemotherapy populations [14]. Goal setting,
self-monitoring and feedback are likely to be key tech-
niques for encouraging individual behaviour change [15].
Motivational interviewing (MI) techniques show how a
counsellor can use an individual’s concerns and needs as
a basis for movement towards a goal [16]. Furthermore,
an evidence synthesis by the National Cancer Survivor-
ship Initiative (NCSI) highlights self-efficacy as a key
component of effective self-management interventions
[17]. The use of physiological feedback, for example a
physical activity monitor, can be a powerful tool to
promote self-efficacy [18, 19]. The NCSI work also iden-
tifies that information alone ‘can increase knowledge and
prepare patients for change, and should be provided for
all survivors’, but ‘additional tailored support from
healthcare professionals’ will be needed for some [17].Identifying patients who require additional support re-
mains a challenge, but evidence suggests they may be
experiencing fatigue and/or anxiety, lacking in a sup-
portive network or have a diagnosis other than invasive
ductal carcinoma [20].
The value of education alone, relative to any add-
itional benefit from supportive guidance/contact with
a health professional, is unclear when treating cancer-
related fatigue. The current intervention has been de-
signed to be consistent with the aspiration of a stan-
dardised intervention that is deliverable in a future
trial by a range of trained health professionals com-
pared to a fully flexible intervention that may rely on
the skills of a professional counsellor: the two inter-
ventionists in the current study both have experience
of counselling theory and practice. Most cancer-
related fatigue studies have been carried out with pa-
tients who have developed long-term problems, often
from heterogeneous patient groups. The aim of the
current work is to prevent long-term problems arising
within a homogenous population. Of the research
conducted around treatment, most involves patients
receiving chemotherapy rather than radiotherapy. This
feasibility study seeks to clarify the preceding uncertainties
by testing a psycho-educational behavioural intervention,
delivered early in the radiotherapy pathway, to help pa-
tients with stage 0–IIIa disease self-manage fatigue.
The primary aim of our feasibility study is to evaluate
trial processes to determine if the design is feasible and
acceptable to deliver in the radiotherapy pathway. The
secondary aim is to evaluate a participant’s experiences
and opinions of the intervention, as a basis for refine-
ment for a definitive trial.Methods
Study design
A pragmatic parallel-group, randomised feasibility trial
(ISRCTN 10303368). Participants will be screened for
fatigue risk and dichotomised into low/high risk groups.
The higher risk group will comprise the feasibility trial
participants, who will be randomly allocated to ‘behav-
ioural intervention’ or ‘education alone’ groups, in the
ratio 2:1. Participants at a lower risk of fatigue will join a
fatigue risk score validation group: this validation work
is required before use in a prospective definitive study. A
schema of participant pathways for both groups is
shown in Fig. 1.Study setting and participant selection
This single-site study will be conducted at a regional
cancer centre (referred to as ‘the cancer centre’), which
provides non-surgical specialist cancer services to a di-
verse population of 1.5 million in south east Wales.
Fig. 1 Study schema
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The radiotherapy planning clinical team will screen con-
secutive patients for initial approach based on the eligi-
bility criteria outlined below. For patients who have not
been prescribed adjuvant chemotherapy, screening will
be done when the planning lists are compiled using the
cancer centre’s electronic patient records system. For pa-
tients receiving adjuvant chemotherapy prior to radio-
therapy, their medical notes will be screened at their
point of consent for radiotherapy (typically chemother-
apy cycle four or five of six).
Inclusion and exclusion criteria
Patients meeting any of the following criteria may be
included in the study: Females > 16 years;
 Diagnosis of stage 0–IIIA breast carcinoma;
 Standard 4000 cGy in 15 fractions over 3 weeks ±
nodal irradiation ± tumour bed boost;
 Able to complete outcome measures.
Patients will be eligible if they have received prior
chemotherapy or are receiving monoclonal antibodies
or endocrine treatment as maintenance therapy.
If any of the following criteria apply, patients cannot
be included in the study:
 Not prescribed radical radiotherapy;
 Concurrent chemotherapy;
 Serious comorbidity causing chronic fatigue;
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intervention;
 Too ill to engage with the intervention in the
opinion of the clinical care team.Recruitment process
Patients’ usual care involves visiting the cancer centre
for a scan from which their radiotherapy treatment is
planned. Timings vary, but this typically happens 3 weeks
before starting treatment. After their planning scan, a
clinical member of the planning team will briefly outline
the study to patients. Eligible and willing patients will be
introduced to the researcher (SG or NC) and have the
opportunity to discuss the study. People who are inter-
ested in the study will be given an invitation pack con-
taining a letter of invitation, patient information leaflet,
model consent form and a prepaid reply slip (labelled
with an anonymised study number.) If a researcher is
not available, then a briefed pre-treatment radiographer
can give the patient a study pack. Patients can indicate
their interest by posting the reply slip (within 5 days) or
by choosing on the day to receive a telephone call within
7 days. All patients expressing interest in participating in
the study, via face-to-face invitation or the reply slip, will
be contacted by telephone to discuss the study. All pa-
tients will be given a minimum of 24 h after the initial
invitation before being phoned and will have the oppor-
tunity to have any questions answered. Study eligibility
will be checked and fatigue risk status measured in pa-
tients who express a wish to participate.Fatigue risk status
Participant risk status will be screened using the Fatigue
Risk (Propensity) Score (Fatigue Propensity Score = [3
+ (0.13 × fatigue) + (0.16 × anxiety) + 1.1 if diagnosis is
not invasive ductal cancer]) [20]. We previously devel-
oped this tool to generate a fatigue risk percentage based
on pre-treatment factors, as a means to identify patients
who are experiencing clinically significant fatigue or are
at higher risk of developing fatigue during radiotherapy.
The score was generated from study data evaluating var-
iables that contribute to RRF [9]. This data was drawn
from 100 women undergoing radiotherapy for breast
cancer, none of whom had received prior chemotherapy.
Performance of the tool will therefore be evaluated in
women who have and have not received chemotherapy.
The risk score is weighted towards fatigue level, but the
other two items independently add predictive ability. A
score of between 3 and 15 is generated. A threshold for
high risk can then be applied, which represents a trade-
off between sensitivity and specificity, in accordance
with clinical judgement or resource constraints [20]. It is
anticipated that approximately 50% of patients will score≥ 5, a threshold that has demonstrated good prediction
of patients as fatigued or not fatigued.
 Scoring ≥ 5 will initiate randomisation to one of the
feasibility trial arms.
 Participants scoring ≥ 5, who decline entry into the
feasibility trial will be offered the opportunity to
enter the ‘fatigue risk score validation group’.
 Patients scoring < 5 will join the ‘fatigue risk score
validation group’. Participants in this group will be
sent a pack containing a consent form and two
fatigue questionnaires to be completed at the end of
their radiotherapy treatment.
Sample size
We aim to recruit approximately 77 participants across
all study groups. Assuming a 10% loss to follow-up, this
will yield final sample sizes of 20, in the intervention
group, and approximately 10 and 40 in the control and
fatigue risk score validation groups, respectively. These
figures are based on logistical grounds and are informed
by previous experience in this setting. Assuming a 50%
recruitment rate, we would need to approach about 160
eligible women across the 12-month study duration to
achieve our planned sample. Recruitment will close
when 20 participants have been recruited to the inter-
vention arm.
Informed consent
The researcher will arrange a mutually convenient date
and venue for patients to give consent for the trial. This
should typically happen within 10 days of invitation, to
enable participants to be allocated to the respective
group with sufficient time before their start of radiother-
apy. The patient’s written consent will be obtained using
the study consent form. Baseline measures will then be
completed and the allocation decided via a central ran-
domisation service. The researcher will explain and leave
the appropriate study pack with the participant.
Group allocation
The nature of the intervention means it will not be pos-
sible to blind either the researcher or participants to
their arm allocation. Analysis of outcome measures will
be conducted blind to participant allocation where pos-
sible. Randomised group allocation and retention of ran-
domisation codes will be via a central online database
service [www.sealedenvelope.com] [21]. This remote al-
location service removes the possibility of the researcher
influencing group allocation. Allocation to the behav-
ioural intervention arm will be in the ratio 2:1 using a
permuted block protocol. A stratification variable will be
age (< 57 years and ≥ 57 years). The researcher will in-
form the psychology team delivering the intervention of
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tically possible via a standard referral form. These partici-
pants will then be discussed at a psychology team meeting
before allocation to one of the two interventionists.
The behavioural intervention
The intervention was developed by JArm and King’s Col-
lege London psychology colleagues [14]. Elements are in-
formed by a CBT model of symptom management—the
objective being to self-manage fatigue by altering associ-
ated thoughts and behaviours. Elements of MI will be in-
corporated to make sure that individual needs are the
starting point to encourage movement towards behav-
ioural goals [16, 17]. The reward (reinforcement) is that in
the future the participant may have less fatigue.
The function of the intervention is to motivate helpful
behaviour change. The intervention is built on four main
components:
 Education—written and verbal information about
fatigue to increase understanding of fatigue, its
causes and consequences. The education content is
informed by the Macmillan Cancer Support booklet
‘Coping with Fatigue’ [22];
 Motivation to change—the counsellor works to
promote self-efficacy and uses persuasive motivational
language and assesses the participants’ commitment/
readiness to change;
 Goal setting and behavioural regulation through self-
monitoring of behaviour—to help people plan for
and achieve the future goals that are meaningful to
the person’s life. These goals may be adjusted with
time. All intervention participants will be asked to
wear a physical activity monitor, which may be used
to set and monitor activity goals according to indi-
vidual preference;
 Emotional support—to help anticipate any negative
emotions/barriers (positive language is used to
stimulate positive feelings, motivation and
importantly enable action.)
The intervention has been coded by a psychologist
using the Behaviour Change Taxonomy (BCT) (http://
www.bct-taxonomy.com/), which has been developed to
identify the active components of behavioural change in-
terventions [23]. The key components are:
 Used a lot throughout: knowledge, goals and
behavioural regulation;
 Moderate use of: intentions, reinforcement, emotion;
 Some use of: beliefs about capabilities, optimism,
beliefs about consequences;
 And a little use of: professional role and identity and
social influences.The intervention will be delivered on an individual
basis. It comprises three 60-min sessions per participant.
The sessions (Table 1) will be delivered face-to-face in
the psychology department counselling room at the can-
cer treatment centre and scheduled to coincide with
treatment appointments at crucial phases in the treat-
ment pathway: (i) start of week one of radiotherapy, (ii)
fatigue intensifies after 10 fractions and (iii) treatment
finishes after 15 fractions (or 20 fractions if a tumour-
bed boost has been prescribed). One of two professionals
attached to the local psychology team (JA and MS) will
deliver the sessions. JA is an experienced counsellor and
MS is a review radiographer who works holistically with
patients during their radiotherapy. A skeleton plan pro-
vides some standardisation of session components.
Within this structure, the content of the sessions is
adaptable to make sure the interaction meets individual
needs. Where a patient has routinely completed a holis-
tic needs assessment, this information will help initiate
this process of individualisation.
Quality assurance of the behavioural intervention
Intervention training will include the theoretical basis
for the intervention and a detailed overview of the man-
ual. The counsellor will record the use of goal setting,
activity monitors and any other relevant use of the inter-
vention. Sessions will be audio-taped to enable integrity-
to-manual checks. An independent assessor will evaluate
fidelity and the extent to which the underlying theory is
used for the first three intervention sessions and a ran-
dom selection of later sessions.
The ‘education alone’ intervention
Participants allocated to the ‘education alone’ trial arm
will be given the Macmillan Cancer Support booklet
called Coping with Fatigue [22]. This booklet is freely
available at information stands within the cancer centre.
The content provides information about fatigue and sug-
gests ways of coping with it.
Fatigue risk score validation group
Participants who are predicted to be at a low risk of fa-
tigue will be allocated to a validation group. These
women will fill in a Functional Assessment of Chronic
Illness Therapy (FACIT-F) Fatigue Scale [24] on the last
day of their treatment and at 10 days and 6 months after
their radiotherapy finishes. Any patients estimated to be
at a higher risk of fatigue who have declined entry into
the feasibility trial will be offered the opportunity to
enter the validation group. The fatigue data from the
trial control arm participants will also be included. The
group data will be correlated to the fatigue risk score
calculated before treatment and thereby enable an as-
sessment of the accuracy of the prediction tool. Analysis
Table 1 Summary of intervention components
Time Content Behaviour change technique/construct/label
Call 0
After
randomisation
Brief scene setting telephone call
Introduce counsellor. Prepare for sessions and agree
dates for future sessions
Session 1
Within first few
RT treatments
Assessment of current energy state
Clarify patterns, causes and impacts of fatigue
Identify individual goals and concerns and the
meaning of fatigue for this person’s life during RT
Assess readiness to change
Consider barriers to change
Set three ‘SMART’ goals
• Activity and sleep diaries and booklet
• Education about fatigue and radiotherapy
• Emotional support and encouragement
KNOWLEDGE—of antecedents and health consequences
EMOTION—self-assessment of affective consequences
BEHAVIOURAL REGULATION—self-monitoring of behaviour
BELIEFS ABOUT CAPABILITIES—verbal persuasion to boost self-efficacy
Goal setting (outcome and behaviour)
Action planning (including implementation intentions
Session 2
Week 2 of
radiotherapy
Review of fatigue state
Review of diary
Guidance with how to manage fatigue and
meet goals
Prioritisation of activities
Best utilisation of upcoming radiography review clinic
GOALS—review of outcome and behaviour goals
BEHAVIOUR REGULATION—self-monitoring of behaviour
BELIEFS ABOUT CONSEQUENCES—comparative imagining of
future outcomes
INTENTIONS—commitment
GOALS—review of outcome goals
Increased self-efficacy, control and positive mood
Session 3
Week 3 of
radiotherapy
Looking to end of treatment and beyond
Weekly planner and diary review
Modification of activity and goal scheduling
Positivity
Self-efficacy
Social support
BEHAVIOUR REGULATION—self monitoring of behaviour
GOALS—review behaviour goals
Goal setting—outcome and behaviour goals
Encourage self-monitoring and modification of goals;
INTENTION—commitment
Identification of ambivalent/unhelpful thoughts about end of treatment and
beyond; enhancement of approach coping by adopting alternative thoughts
Incremental increase in activity levels to achieve goals; normalisation after
treatment
OPTIMISM—verbal persuasion to boost self-efficacy
EMOTION—reduce negative emotions
SOCIAL INFLUENCES—social support or encouragement (general)
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apy. The predictive ability of the tool will be evaluated
with a view to potential use in selecting participants in
an effectiveness trial.
Study assessments
At screening
The patient’s cancer diagnosis and reasons for ineligibil-
ity will be recorded. A screening log will be maintained
that records the numbers of people who:
 Are eligible/ineligible;
 Are approached;
 Decline to be contacted and reasons for declining (if
proffered);
 Score above and below the fatigue score threshold;
 Decline at the point of consent or trial group
allocation.
Trial group baseline measures
Baseline outcome measures should be completed directly
after consent and prior to random allocation to a trial
arm. This will either happen at the cancer centre or the
person’s home, depending upon individual preference.
The following demographic and clinical data will berecorded on the pre-treatment case report form (CRF)
before randomisation:
 Date of birth and postcode;
 Cancer diagnosis and pathological stage and grade;
 Employment status;
 Adjuvant therapies prescribed
 History of previous or concurrent treatments for
this cancer—surgery, chemotherapy, endocrine
therapy;
 Other relevant medical health history including
mental health issues.
Trial outcome measures
The feasibility outcomes will include an evaluation of
outcome measure completion rates. Outcome measures
include Functional Assessment of Chronic Illness Ther-
apy Fatigue Scale (FACIT-F) [24], Hospital Anxiety and
Depression Scale (HADS) [25], European Organisation
for Research and Treatment of Cancer quality of life
physical functioning subscale (EORTC-QLQc30 version
3.0) [26], physical activity as measured by the Fitbit Alta
activity tracker and Amy Hoffman’s Self-Efficacy for
Managing Chronic Disease scale [27]. The primary end-
point is fatigue as measured by the FACIT-F 10 days
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stratified by prior chemotherapy/no prior chemotherapy.
The schedule of outcome measures is shown in
Table 2. Scale outcome measures will be self-reported by
participants (presumed to be at their home). One phone
call will be made to prompt a response if outcome mea-
sures have not been returned within 7 days of being due.
If participants discontinue with intervention, then any
completed outcome measurements will be retained for
analysis with participant consent.
Trial process evaluations
The feasibility and acceptability of the trial processes will
be evaluated with mixed-methods.
Evaluation of the feasibility of the trial
 Eligibility rate will be calculated as the proportion of
women with stage 0–IIIa breast cancer on
radiotherapy clinic lists who also meet the eligibility
criteria;
 Recruitment rate will be calculated as the number of
people who consent to participate divided by the
number of eligible patients approached;
 Eligible patients who decline to enter will be asked
to volunteer a reason;
 Retention rate will be calculated as the number of
participants who complete all outcome measures
divided by the number who record baseline outcome
measures;
 Adherence to the intervention will be monitored by
recording the number of sessions completed;
 Reasons for discontinuation or non-adherence
should be sought, where possible.
The definitive trial will be considered feasible if > 70%
of participants complete all the interventions and out-
come measures. If this rate is between 65 and 70%, then
adjustments in future work should be considered. A rate
< 65% requires substantive change to the intervention
and/or to the trial process.Table 2 Schedule of trial outcome measures
Outcome measure Pre-RT Week 2 Week 3
After 10 fractions of RT After 15 f
Baseline On treatment
T0 T1 T2
FACIT-F X X X
HADS X
Physical activity X X
EORTC-QLQc30 X X
Amy Hoffman’s self-efficacy X XAcceptability
Patient participant’s and interventionists’ views on the
acceptability of intervention and trial processes will be
captured in semi-structured telephone interviews. All in-
terviews will be recorded with the interviewee’s permis-
sion. Questions to understand if, and how, changes in
thoughts or behaviour are initiated and sustained will be
based upon the active ingredients identified at coding
theory of BCT. Analysis will be inductive, with new
themes being incorporated into subsequent interviews.
Interviews will be conducted with about eight inter-
vention patients. The aim is to conduct participant inter-
views within 2 months of the end of their radiotherapy
sessions. A sample will be chosen that reflects maximum
variation in compliance with and response to the inter-
vention. Interviews will also be conducted with two con-
trol group participants to explore acceptability of trial
processes, any impacts of participation and use of the
educational booklet. Interviews will last up to 40 min
and will be stopped if the interviewee becomes too fa-
tigued or distressed.
This enquiry will be supplemented by an in-depth
interview with both of the professionals delivering the
intervention. These semi-structured interviews will ex-
plore challenges to delivery, perceived successes, barriers
to implementation/suggestions to improve intervention
processes and opinion of whether the intervention was
delivered as intended. The perceived value of the inter-
vention and factors that promote or inhibit patient ad-
herence and integration into daily life will be explored.Data analysis
The study can be considered as the modelling phase of
the Medical Research Council guidelines for developing
complex interventions [28]. As a feasibility study, the
purpose is not to make a formal analysis of the primary
outcome. The purpose is evaluation of trial processes to
determine whether to progress to a study of effectiveness
and to estimate unknown parameters needed to design
this study.+ 10 days + 3 weeks + 6 months
ractions of RT 10 days after RT 3 weeks after RT 6 months after RT
Follow-up
T3 T4 T5
X X X
X X
X X
X
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allocation where possible. Feasibility descriptive data will
evaluate eligibility, recruitment and retention rates and
acceptability of and adherence to the intervention with
mean/median point statistics and 95% confidence inter-
vals. Changes over time of the outcome measures will be
described by group. Adherence rates according to base-
line measures may be analysed to assess the role of me-
diators, such as prior chemotherapy prescription.
All interviews will be recorded and transcribed. Data
analysis will be performed using a framework approach
[29]. A coding framework for emergent themes will be
developed, validated and compared. Twenty percent of
the data will be double-coded by a second researcher to
check reliability of coding to enhance rigour.
Ethical considerations
The study was approved by a local NHS research ethics
committee in August 2016 (16/WA/0205) and will be
conducted in accordance with the principles of Good
Clinical Practice (GCP). The ethical permission granted
permission to collect reasons as to why women decline
to participate to inform the evaluation of feasibility of
the study. The study has also been approved by the local
National Health Service Research and Development
committee.
Safety monitoring
All potentially serious adverse events related to the be-
havioural intervention will be reported to the principal
investigator within 24 h of the team being aware of its
occurrence. The psychology team will consider each re-
ferral to the intervention delivery team at a team meet-
ing, in line with the cancer centre’s standard operating
procedures. This will include a consideration of any
known support that may have been sought or offered
(internally or externally to the cancer centre) for psycho-
logical concerns. Participants will be informed if they
score > 19 on the HADS and the option of notifying
their GP will be discussed with them.
Dissemination policy
This protocol (version 2.0, date 14 December 2016) has
been reported in line with SPIRIT guidance [30]. The
findings will first be reported to the funders, then com-
municated to participants. At least one open access pub-
lication and conference presentation will disseminate
results to relevant health professionals within 12 months
of the trial closing. All members of the overseeing trial
advisory group (TAG) will be invited to be co-authors.
Discussion
Fatigue is the biggest patient concern before, during and
after radiotherapy for women with early breast cancer[31]. Our group’s previous exploratory and observational
work indicates that approximately 60% of women experi-
ence mild fatigue that does not greatly disrupt lives [9].
However, we have also used our Fatigue Risk Score to
evidence a distinct patient group who are at high risk of
fatigue before radiotherapy [20]. Many factors can con-
tribute to fatigue, but women with raised levels of per-
ceived stress before treatment are most at risk from later
behavioural problems like fatigue [9, 32]. Furthermore,
maintenance and pacing of activity is important, but the
short-term adoption of vigorous exercise is likely to be
counterproductive for patients at a high risk of fatigue.
The current study builds on the preceding develop-
mental work by refining and testing an intervention to
reduce fatigue. This intervention is novel because it is
instigated early in the radiotherapy pathway to target the
women who are most likely to benefit (any reduction in
fatigue for low-risk women is likely to be very small).
The aim is to support coping using behavioural tech-
niques. A strength of the study is the homogeneity of
the participants’ disease and treatment characteristics.
Although appropriate outcome measures to test for ef-
fects are being used as part of the study protocol, the
trial is neither designed nor powered for formal analysis
of effectiveness. The purpose is to address the current
uncertainties in optimal trial and intervention design to
inform a future definitive trial.
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